Too much slowing: In some people, food can remain in the stomach for longer than normal, leading to reflux, discomfort, or rarely a condition called gastroparesis
Other patients see the weight loss at higher doses
Most providers recommend a four-to-eight week trial period
Proper subcutaneous injection practices minimize exposure of the reconstituted peptide to contamination and ensure accurate dose delivery
Listed effects of GLP-1 include: 1) reduced glucagon secretion from the liver (thereby slowing down the release of glucose, or blood sugar, into the bloodstream during periods of fasting or reduced food intake), 2) increased insulin production, 3) decreased appetite, and 4) decreased intestinal motility (causing food to move slower through the digestive system, thereby further improving blood sugar and reducing appetite)